These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26370183)

  • 1. Suboptimal Dosing Parameters as Possible Factors in the Negative Phase III Clinical Trials of Progesterone for Traumatic Brain Injury.
    Howard RB; Sayeed I; Stein DG
    J Neurotrauma; 2017 Jun; 34(11):1915-1918. PubMed ID: 26370183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Another failed attempt of neuroprotection: progesterone for moderate and severe traumatic brain injury.
    Meyfroidt G; Taccone FS
    Minerva Anestesiol; 2016 Apr; 82(4):486-91. PubMed ID: 26126980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of individual clinical outcomes on trial participants' perspectives on enrollment in emergency research without consent.
    Whitesides LW; Baren JM; Biros MH; Fleischman RJ; Govindarajan PR; Jones EB; Pancioli AM; Pentz RD; Scicluna VM; Wright DW; Dickert NW
    Clin Trials; 2017 Apr; 14(2):180-186. PubMed ID: 28359192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone neuroprotection: The background of clinical trial failure.
    Schumacher M; Denier C; Oudinet JP; Adams D; Guennoun R
    J Steroid Biochem Mol Biol; 2016 Jun; 160():53-66. PubMed ID: 26598278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Embracing failure: What the Phase III progesterone studies can teach about TBI clinical trials.
    Stein DG
    Brain Inj; 2015; 29(11):1259-72. PubMed ID: 26274493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone in traumatic brain injury: time to move on to phase III trials.
    Vandromme M; Melton SM; Kerby JD
    Crit Care; 2008; 12(3):153. PubMed ID: 18522765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralipid Vehicle Does Not Interfere with the Efficacy of Progesterone in Attenuating Edema following Traumatic Brain Injury.
    Wali B; Stein DG; Sayeed I
    J Neurotrauma; 2017 Jul; 34(13):2183-2186. PubMed ID: 28075214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone for neuroprotection in pediatric traumatic brain injury.
    Robertson CL; Fidan E; Stanley RM; Noje C; Bayir H
    Pediatr Crit Care Med; 2015 Mar; 16(3):236-44. PubMed ID: 25581631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External Validation of the International Mission for Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury: Prognostic Models for Traumatic Brain Injury on the Study of the Neuroprotective Activity of Progesterone in Severe Traumatic Brain Injuries Trial.
    Sun H; Lingsma HF; Steyerberg EW; Maas AI
    J Neurotrauma; 2016 Aug; 33(16):1535-43. PubMed ID: 26652051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Progesterone for Acute Traumatic Brain Injury: a Meta-analysis of Randomized Controlled Trials.
    Wang Z; Shi L; Ding W; Shao F; Yu J; Zhang J
    Mol Neurobiol; 2016 Dec; 53(10):7070-7077. PubMed ID: 26676571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very Early Administration of Progesterone Does Not Improve Neuropsychological Outcomes in Subjects with Moderate to Severe Traumatic Brain Injury.
    Goldstein FC; Caveney AF; Hertzberg VS; Silbergleit R; Yeatts SD; Palesch YY; Levin HS; Wright DW
    J Neurotrauma; 2017 Jan; 34(1):115-120. PubMed ID: 26973025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Female Sex Steroids Administration on Pathophysiologic Mechanisms in Traumatic Brain Injury.
    Khaksari M; Soltani Z; Shahrokhi N
    Transl Stroke Res; 2018 Aug; 9(4):393-416. PubMed ID: 29151229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone for Traumatic Brain Injury: A Meta-Analysis Review of Randomized Controlled Trials.
    Lu XY; Sun H; Li QY; Lu PS
    World Neurosurg; 2016 Jun; 90():199-210. PubMed ID: 26960278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone Provides the Pleiotropic Neuroprotective Effect on Traumatic Brain Injury Through the Nrf2/ARE Signaling Pathway.
    Zhang M; Wu J; Ding H; Wu W; Xiao G
    Neurocrit Care; 2017 Apr; 26(2):292-300. PubMed ID: 27995513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Very early administration of progesterone for acute traumatic brain injury.
    Wright DW; Yeatts SD; Silbergleit R; Palesch YY; Hertzberg VS; Frankel M; Goldstein FC; Caveney AF; Howlett-Smith H; Bengelink EM; Manley GT; Merck LH; Janis LS; Barsan WG;
    N Engl J Med; 2014 Dec; 371(26):2457-66. PubMed ID: 25493974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical trial of progesterone for severe traumatic brain injury.
    Skolnick BE; Maas AI; Narayan RK; van der Hoop RG; MacAllister T; Ward JD; Nelson NR; Stocchetti N;
    N Engl J Med; 2014 Dec; 371(26):2467-76. PubMed ID: 25493978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of progesterone administration on the prognosis of patients with severe traumatic brain injury: a meta-analysis of randomized clinical trials.
    Pan ZY; Zhao YH; Huang WH; Xiao ZZ; Li ZQ
    Drug Des Devel Ther; 2019; 13():265-273. PubMed ID: 30666088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials in traumatic brain injury: current problems and future solutions.
    Maas AI; Marmarou A; Murray GD; Steyerberg EW
    Acta Neurochir Suppl; 2004; 89():113-8. PubMed ID: 15335110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is progesterone a worthy candidate as a novel therapy for traumatic brain injury?
    Stein DG
    Dialogues Clin Neurosci; 2011; 13(3):352-9. PubMed ID: 22033509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats.
    Wali B; Sayeed I; Guthrie DB; Natchus MG; Turan N; Liotta DC; Stein DG
    Neuropharmacology; 2016 Oct; 109():148-158. PubMed ID: 27267687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.